1. Home
  2. ARW vs IONS Comparison

ARW vs IONS Comparison

Compare ARW & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrow Electronics Inc.

ARW

Arrow Electronics Inc.

HOLD

Current Price

$113.39

Market Cap

5.8B

Sector

Technology

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$79.33

Market Cap

12.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARW
IONS
Founded
1935
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
12.3B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
ARW
IONS
Price
$113.39
$79.33
Analyst Decision
Sell
Strong Buy
Analyst Count
2
22
Target Price
$102.00
$82.82
AVG Volume (30 Days)
492.8K
2.2M
Earning Date
02-05-2026
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
0.79
N/A
EPS
9.05
N/A
Revenue
$29,389,382,000.00
$966,957,000.00
Revenue This Year
$9.50
$29.66
Revenue Next Year
$4.23
$1.88
P/E Ratio
$12.50
N/A
Revenue Growth
3.16
20.41
52 Week Low
$86.50
$23.95
52 Week High
$134.74
$83.61

Technical Indicators

Market Signals
Indicator
ARW
IONS
Relative Strength Index (RSI) 54.76 54.94
Support Level $110.34 $76.70
Resistance Level $116.94 $81.00
Average True Range (ATR) 2.72 2.12
MACD 0.32 -0.62
Stochastic Oscillator 62.04 38.11

Price Performance

Historical Comparison
ARW
IONS

About ARW Arrow Electronics Inc.

Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: